Gateway 2011: Ropack Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: Ropack Inc.



Your online Gateway to Ropack Inc. in 2011

10801 Mirabeau Street,
Montreal QC H1J 1T7
513 846-0921
www.ropack.com

About Ropack Inc.

 

Watch our video

 

Ropack offers turnkey primary and secondary pharmaceutical packaging services of solid oral dosages, tablets, powder, and encapsulation into blisters, pouches, bottles, stick packaging and carded blisters. Ropack recently added syringe assembly and vial labeling capabilities. Facilities are cGMP compliant, FDA certified and have 25 Class 100000 production rooms. Ropack is competitive, flexible and agile, supporting clinical trials, short-run start-ups, commercial production for more than 100 U.S., Canadian and European pharmaceutical customers.

 

Ropack has more than ten years of experience packaging temperature- and humidity-sensitive materials.  Our proven record of accomplishment in new product launches will support and accelerate your go-to-market timeline.

See what's new from Ropack's turnkey primary and secondary pharmaceutical and nutraceutical packaging services, including the latest advancements in blisters at Interphex 2011.Now Ropack offers stick packaging – slim, tube-shaped uni-dose packaging of solid oral dosage in a low relative humidity, controlled residual oxygen and temperature-controlled environment.  Stick packaging is popular in Japan and Europe for its accuracy and convenience, and now Ropack is advancing stick packaging technology in North America. 

Ropack now offers manufacturing and packaging environments to meet even the most exacting specifications.  A new 15,000-square-foot dedicated production suite is temperature-controlled with low RH (20%) and controlled residual oxygen (< 2%). Like all Ropack facilities, it is cGMP compliant, FDA certified and Health Canada approved.

 

New Products
and Releases
New Whitepapers

Ropack Enhances Services with Controlled Production Environment

Stick packaging

 

 

For more information:

To schedule a meeting, call or text Paul Dupont, Director of Business Development, at 513 846-0921, or email him: paul.dupont@ropack.com.

 

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here